With further validation, this approach may serve as a clinically practical tool for reliable detection of FAME1 and for broader screening of other FAME subtypes, potentially reducing reliance on prolonged clinical observation or specialized electrophysiological testing. This evidence concerns the gene SAMD12 and benign adult familial myoclonic epilepsy.